Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05036005
Other study ID # IFG-08-2019
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date July 11, 2021
Est. completion date July 2023

Study information

Verified date April 2023
Source Institut fuer Frauengesundheit
Contact NeoON Study Manager
Phone +49 9131 9279136
Email neo.on@ifg-erlangen.de
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The treatment of patients with HER2 positive early breast cancer has continuously improved over the last decades. Up to now both, trastuzumab and pertuzumab are approved in combination with chemotherapy (CTX) not only for the adjuvant but also for the neoadjuvant treatment of early breast cancer patients. A high pCR rate in the neoadjuvant setting was shown in several trials and observational studies with CTX+ trastuzumab and with CTX+ pertuzumab. The efficacy is dependent on a variety of mechanisms including the blocking of the important PI3K/Akt and MAPK pathways, and ADCC (antibody dependent cellular toxicity). Recently the biosimilar Ontruzant® (SB3) has been introduced into the treatment of HER2 positive breast cancer as a biosimilar. Efficacy and toxicity have been shown to be equivalent to the first approved antibody, however, data from the real-world setting have not been published like it has for the originally approved antibody. Therefore, the aim of this study is to establish safety and efficacy for Ontruzant® in the real world setting. Patients can be included if they are treated with Ontruzant® in the neoadjuvant setting. Additionally, the study will be accompanied by a comprehensive immune monitoring program and biomarker program to explore immune oncology potential for the neoadjuvant treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 108
Est. completion date July 2023
Est. primary completion date April 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Written informed consent prior to beginning of trial specific procedures. 2. Subject must be female and aged = 18 years on day of signing informed consent. 3. ECOG 0-1. 4. Histologically confirmed, early HER2 positive breast cancer determined by core biopsy of breast tumor lesion. 5. Measurable tumor lesion with a size of = 1 cm assessed by sonography or magnetic resonance imaging (MRI) within = 28 days prior to entry. In case of inflammatory disease, the extent of inflammation will be measured. 6. Indication for chemotherapy. 7. Multicentric and/or multifocal disease as well as synchronous bilateral breast cancer is eligible as long as one measurable lesion meets all inclusion criteria. The investigator has to determine which lesion will be used for tumor evaluation before initiation of treatment. 8. Complete staging within 8 weeks prior to entry with no evidence of distant disease, including bilateral mammography, breast ultrasound, chest-X-ray (or chest CT-scan), liver ultrasound (or liver CT-scan or liver MRI) and bone scan. 9. Subjects must provide a core biopsy from tumor lesion before first chemotherapy, after 3 cycles of chemotherapy and after last neoadjuvant study treatment for biomarker analyses. 10. Adequate organ function defined as: Absolute neutrophile count =1500/µL, Platelets =100 000/µL, Hemoglobin =10.0 g/dL or =6.2 mmol/L, Creatinine =1.5 × ULN OR measured or calculated creatinine clearance =30 mL/min for participant with creatinine levels >1.5 × institutional ULN (GFR can also be used in place of creatinine or CrCl), Total bilirubin =1.5 ×ULN OR direct bilirubin =ULN for participants with total bilirubin levels >1.5 × ULN, AST (SGOT) and ALT (SGPT) =2.5 × ULN (=5 × ULN for participants with liver metastases), International normalized ratio (INR) OR prothrombin time (PT) =1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT is within therapeutic range of intended use of anticoagulants, LVEF > 50 % 11. Female subjects of childbearing potential must have a negative urine pregnancy test within 72 h prior to study entry and be willing to use an adequate method of contraception for course of the study through 7 months after the last dose of trial treatment. Exclusion Criteria: 1. Concurrent participation in a study with an investigational agent/device or within 14 days of study entry. 2. Prior chemotherapy, radiation therapy or small molecule therapy for any reason. 3. Previous malignant disease being disease-free for less than 3 years (except in situ carcinoma of the cervix and basal cell carcinoma of the skin). 4. Pregnancy or lactation. 5. Prior neoadjuvant therapy. 6. Active infection requiring systemic therapy. 7. History of (non-infectious) pneumonitis that required steroids or current pneumonitis. 8. Active autoimmune disease or other diseases that requires systemic treatment with corticosteroids or immunosuppressive drugs (physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency is allowed). 9. History of primary or acquired immunodeficiency (including allogenic organ transplant). 10. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis). 11. Known history of following infections: Human immunodeficiency virus (HIV), History of acute or chronic Hepatitis B or Hepatitis C, has received a live-virus vaccination within 30 days of planned treatment start. Seasonal flu vaccines that do not contain live virus are permitted. 12. Known congestive heart failure > NYHA I and/or coronary heart disease, angina pectoris, previous history of myocardial infarction, uncontrolled or poorly controlled arterial hypertension (e.g. blood pressure >160/90 mmHg under treatment with two or more antihypertensive drugs), rhythm disorders with clinically significant valvular heart disease. 13. Pre-existing motor or sensory neuropathy of a severity grade =2 by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0. 14. Any other condition in opinion of the investigator that would interfere with applied systemic treatment or other trial procedures.

Study Design


Intervention

Drug:
Ontruzant
All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.
Chemotherapy
All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Choice of chemotherapy is at the discretion of the investigator
Pertuzumab
All patients will receive an initial dose of Ontruzant® i.v. 8 mg/kg b.w in combination with standard chemotherapy with or without pertuzumab i.v. 480 mg followed by 5 cycles of Ontruzant® i.v. 6 mg/kg b.w. q21d in combination with standard chemotherapy with or without pertuzumab i.v. 420 mg. Addition of pertuzumab is at the discretion of investigator's decision.

Locations

Country Name City State
Germany Hämato-Onkologische Schwerpunktpraxis am Klinikum Aschaffenburg Aschaffenburg Bavaria
Germany Department for Hematology, Oncology and Tumor Immunology Charité Campus Benjamin Franklin Berlin
Germany Department of Gynecology and Obstetrics, HELIOS Hospital Berlin Buch GmbH Berlin
Germany Department for Gynecology and Obstetrics, Marienhospital Bottrop gGmbH Bottrop North Rhine-Westphalia
Germany Department of Gynecology and Obstetrics, Dresden University Hospital Carl-Gustav Carus Dresden Saxony
Germany Department of Gynecology and Obstetrics, Erlangen University Hospital Erlangen Bavaria
Germany Center for Hematology and Oncology Bethanien Frankfurt Hesse
Germany Department of Gynecology, University Hospital Hamburg-Eppendorf Hamburg Haburg
Germany Division Gynecologic Oncology, Heidelberg University Hospital (UKHD) Heidelberg Baden-Wuerttemberg
Germany Department of Gynecology and Obstetrics, University Medicine Mainz Mainz Hesse
Germany Department of Gynecology, Tübingen University Hospital Tübingen Baden-Wuerttemberg

Sponsors (2)

Lead Sponsor Collaborator
Institut fuer Frauengesundheit Samsung Bioepis Co., Ltd.

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other To assess the antibody-dependent cell mediated cytotoxicity (ADCC) ADCC will be quantified and immune phenotyping will be performed from peripheral blood mononuclear cells (PBMCs). Measured from biomaterial collected at baseline, 12 weeks after treatment initiation and at surgery
Other Fc?R genotypes Germline DNA will be genotyped in order to specify Fc?R polymorphisms and impact of Fc?R genotypes on ADCC and pCR will be assessed. Measured from biomaterial collected at baseline, 12 weeks after treatment initiation and at surgery
Primary Pathological complete response (pCR) rate Pathological complete response (pCR) rate, defined as the complete absence of tumor cells (ypT0; ypN0) after neoadjuvant study treatment of HER2-positive early breast cancer patients treated with Ontruzant® (SB3) in combination with pertuzumab (optional) and a standard chemotherapy. Pathological complete response will be assessed at final surgery.
Secondary Pathological complete response (pCR) rate in patients without pertuzumab Pathological complete response (pCR) rate, defined as the complete absence of tumor cells (ypT0; ypN0) after neoadjuvant study treatment of HER2-positive early breast cancer patients treated with Ontruzant® (SB3) and a standard chemotherapy who were not treated with pertuzumab. Pathological complete response will be assessed at final surgery.
Secondary Number of participants wuth treatment-related adverse events as assessed by CTCAE v5.0 The safety endpoints for the study will include rate of AE/SAEs and fatal SAEs, causality and outcome of AE/SAEs, rate of treatment discontinuations and reasons, Changes in vital signs, laboratory values etc. Grading of AE/SAEs will be based on NCI CTCAE v5.0. Adverse ebents will be assessed from first administration of trial treatment until 30 days after last administration of trial treatment.
Secondary EORTC-QLQ-C30 To evaluate changes in health related quality of life (QoL) assessments from baseline in all subjects using Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Every nine weeks from first administration of trial medication through study completion, up to 30 days after administration of last medication.
Secondary EORTC-QLQ-BR23 To evaluate changes in health related quality of life (QoL) assessments from baseline in all subjects using Quality of Life Questionnaire Breast Cancer-Specific Quality of Life (EORTC QLQ-BR23). Every nine weeks from first administration of trial medication through study completion, up to 30 days after administration of last medication.
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A